Christoffer Knak Goth

Christoffer Knak Goth

Auto-generated profile, based on publicly available information

Christoffer Knak Goth

Department of Surgery, Beth Israel Deaconess Medical Center, National Center for Functional Glycomics, Harvard Medical School, Boston, MA, 02215, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2013 in Nature
Verified
Journal Article
Open access
PDF file
MBMarko T. Boskovski
Marko T. Boskovski
SYShiaulou Yuan
Shiaulou Yuan
NPNis Borbye Pedersen
Nis Borbye Pedersen
CGChristoffer Knak Goth
Christoffer Knak Goth
SMSvetlana Makova
Svetlana Makova
MKMustafa K. Khokha
Mustafa K. Khokha
The O-glycosylation enzyme Galnt11 has an important role in heterotaxy, a disorder of left–right body patterning or laterality: Galnt11 modulates Notch signalling which alters cilia types at the embryonic left–right organizer, therefore determining laterality. A failure to establish correct left–right body patterning during embryogenesis can cause heterotaxy, a rare birth defect involving major congenital heart disease. Mustafa Khokha and colleagues have characterized the role of the GalNAc-type O-glycosylation enzyme, product of the GALNT11 gene associated with human heterotaxy. They found that GALNT11 modulates both Notch signalling and the spatial distribution and ratio of motile and immotile cilia at the embryonic left–right organizer to determine laterality. The study identifies a novel mechanism for human heterotaxy. Heterotaxy is a disorder of left–right body patterning, or laterality, that is associated with major congenital heart disease1. The aetiology and mechanisms underlying most cases of human heterotaxy are poorly understood. In vertebrates, laterality is initiated at the embryonic left–right organizer, where motile cilia generate leftward flow that is detected by immotile sensory cilia, which transduce flow into downstream asymmetric signals2,3,4,5,6. The mechanism that specifies these two cilia types remains unknown. Here we show that the N-acetylgalactosamine-type O-glycosylation enzyme GALNT11 is crucial to such determination. We previously identified GALNT11 as a candidate disease gene in a patient with heterotaxy7, and now demonstrate, in Xenopus tropicalis, that galnt11 activates Notch signalling. GALNT11 O-glycosylates human NOTCH1 peptides in vitro, thereby supporting a mechanism of Notch activation either by increasing ADAM17-mediated ectodomain shedding of the Notch receptor or by modification of specific EGF repeats. We further developed a quantitative live imaging technique for Xenopus left–right organizer cilia and show that Galnt11-mediated Notch1 signalling modulates the spatial distribution and ratio of motile and immotile cilia at the left–right organizer. galnt11 or notch1 depletion increases the ratio of motile cilia at the expense of immotile cilia and produces a laterality defect reminiscent of loss of the ciliary sensor Pkd2. By contrast, Notch overexpression decreases this ratio, mimicking the ciliopathy primary ciliary dyskinesia. Together our data demonstrate that Galnt11 modifies Notch, establishing an essential balance between motile and immotile cilia at the left–right organizer to determine laterality, and reveal a novel mechanism for human heterotaxy.

13 November 2015 in EMBO Reports
Verified
Journal Article
Closed access
PDF file
KSKatrine T Schjoldager
Katrine T Schjoldager
HJHiren J Joshi
Hiren J Joshi
YKYun Kong
Yun Kong
CGChristoffer K Goth
Christoffer K Goth
SKSarah Louise King
Sarah Louise King
HCHenrik Clausen
Henrik Clausen

9 November 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CGChristoffer K. Goth
Christoffer K. Goth
AHAdnan Halim
Adnan Halim
SKSumeet A. Khetarpal
Sumeet A. Khetarpal
DRDaniel J. Rader
Daniel J. Rader
HCHenrik Clausen
Henrik Clausen
KSKatrine T.-B. G. Schjoldager
Katrine T.-B. G. Schjoldager
Significance: Ectodomain shedding is a central event in a range of biological processes and pathways, however the underlying mechanisms are still not fully understood. Here we present evidence that site-specific O-glycosylation regulated by individual GalNAc-Transferase isoforms, serve to coregulate ectodomain shedding, predominantly through blocking of cleavage. Our general finding is exemplified by the specific role of a single GalNAc-T isoform (GalNAc-T2) in coregulating TNF-alpha release in vitro, ex vivo in isogenic cell models, and in vivo in mouse Galnt2 knockouts. Adding the large family of GalNAc-T isoforms to regulation of ectodomain shedding substantially increase the ability to fine-tune this important process on a substrate level.

1 November 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
KSKatrine Ter-Borch Gram Schjoldager
Katrine Ter-Borch Gram Schjoldager
MVMalene B. Vester-Christensen
Malene B. Vester-Christensen
CGChristoffer K. Goth
Christoffer K. Goth
TPThomas Nordahl Petersen
Thomas Nordahl Petersen
SBSøren Brunak
Søren Brunak
HCHenrik Clausen
Henrik Clausen
Site-specific GalNAc-type O-glycosylation is emerging as an important co-regulator of proprotein convertase (PC) processing of proteins. PC processing is crucial in regulating many fundamental biological pathways and O-glycans in or immediately adjacent to processing sites may affect recognition and function of PCs. Thus, we previously demonstrated that deficiency in site-specific O-glycosylation in a PC site of the fibroblast growth factor, FGF23, resulted in marked reduction in secretion of active unprocessed FGF23, which cause familial tumoral calcinosis and hyperostosis hyperphosphatemia. GalNAc-type O-glycosylation is found on serine and threonine amino acids and up to 20 distinct polypeptide GalNAc transferases catalyze the first addition of GalNAc to proteins making this step the most complex and differentially regulated steps in protein glycosylation. There is no reliable prediction model for O-glycosylation especially of isolated sites, but serine and to a lesser extent threonine residues are frequently found adjacent to PC processing sites. In the present study we used in vitro enzyme assays and ex vivo cell models to systematically address the boundaries of the region within site-specific O-glycosylation affect PC processing. The results demonstrate that O-glycans within at least ±3 residues of the RXXR furin cleavage site may affect PC processing suggesting that site-specific O-glycosylation is a major co-regulator of PC processing.

20 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
TMThomas D. Madsen
Thomas D. Madsen
LHLasse H. Hansen
Lasse H. Hansen
JHJohn Hintze
John Hintze
ZYZilu Ye
Zilu Ye
SJShifa Jebari
Shifa Jebari
KSKatrine T. Schjoldager
Katrine T. Schjoldager
Peptide hormones and neuropeptides encompass a large class of bioactive peptides that regulate physiological processes like anxiety, blood glucose, appetite, inflammation and blood pressure. Here, we execute a focused discovery strategy to provide an extensive map of O-glycans on peptide hormones. We find that almost one third of the 279 classified peptide hormones carry O-glycans. Many of the identified O-glycosites are conserved and are predicted to serve roles in proprotein processing, receptor interaction, biodistribution and biostability. We demonstrate that O-glycans positioned within the receptor binding motifs of members of the neuropeptide Y and glucagon families modulate receptor activation properties and substantially extend peptide half-lives. Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.

1 May 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SWShengjun Wang
Shengjun Wang
YMYang Mao
Yang Mao
YNYoshiki Narimatsu
Yoshiki Narimatsu
ZYZilu Ye
Zilu Ye
WTWeihua Tian
Weihua Tian
HCHenrik Clausen
Henrik Clausen
The low-density lipoprotein receptor (LDLR) and related proteins are important for the transport of diverse biomolecules across cell membranes and barriers. Their functions are especially relevant for cholesterol homeostasis and diseases, including neurodegenerative and kidney disorders. Members of the LDLR-related protein family share LDLR class A (LA) repeats providing binding properties for lipoproteins and other biomolecules. We previously demonstrated that short linker regions between these LA repeats contain conserved O-glycan-sites. Moreover, we found that O-glycan modifications at these sites are selectively controlled by the GalNAc-transferase isoform, GalNAc-T11. However, the effects of GalNAc-T11-mediated O-glycosylation on LDLR and related receptors localization and function are unknown. Here, we characterized O-glycosylation of LDLR-related proteins and identified conserved O-glycosylation sites in the LA linker regions of VLDLR, LRP1, and LRP2 (Megalin) from both cell lines and rat organs. Using a panel of gene-edited isogenic cell line models, we demonstrate that GalNAc-T11-mediated LDLR and VLDLR O-glycosylation is not required for transport and cell surface expression and stability of these receptors, but markedly enhances LDL and VLDL binding and uptake. Direct ELISA-based binding assays with truncated LDLR constructs revealed that O-glycosylation increased affinity for LDL by approximately 5-fold. The molecular basis for this observation is currently unknown, but these findings open up new avenues for exploring the roles of LDLR-related proteins in disease.